Mode
Text Size
Log in / Sign up

Systematic review and meta-analysis links Mediterranean diet to improved cardiometabolic markers

Systematic review and meta-analysis links Mediterranean diet to improved cardiometabolic markers
Photo by Logan Voss / Unsplash
Key Takeaway
Consider Mediterranean diet for modest reductions in HbA1c, LDL, and triglycerides in at-risk adults, but note null effects on other markers.

This systematic review and meta-analysis evaluated the effects of Mediterranean diet-based dietary interventions on cardiometabolic risk factors and gut microbiota composition in adults at increased risk for type 2 diabetes and cardiovascular disease. The analysis included 1337 participants from multiple studies.

Compared to control diets, the Mediterranean diet significantly reduced glycated hemoglobin (HbA1c) by -0.18 (95% CI = -0.35, -0.01), LDL cholesterol by -0.10 (95% CI = -0.19, -0.00), and triglycerides by -0.20 (95% CI = -0.28, -0.12). No significant effects were observed for fasting glucose, insulin, HOMA-IR, total cholesterol, or HDL cholesterol.

Gut microbiota analysis showed increased alpha-diversity and enrichment of health-related taxa, including Akkermansia muciniphila and Roseburia spp., though these findings were limited by heterogeneity in sequencing methods and taxonomic reporting.

Adverse events, follow-up duration, and primary outcomes were not reported. The authors noted limitations in the comparability of gut microbiota findings across studies. While the results suggest modest benefits of Mediterranean diet on select cardiometabolic markers, the evidence is derived from a meta-analysis with potential heterogeneity, and causal inferences should be made cautiously.

Study Details

Study typeMeta analysis
Sample sizen = 1,337
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
AIMS: The Mediterranean diet (MedD) is associated with improved metabolic health and modulation of gut microbiota (GM), both relevant to preventing type 2 diabetes (T2D) and cardiovascular disease (CVD). This systematic review and meta-analysis evaluated the effects of MedD-based dietary interventions on metabolic outcomes and GM composition in individuals at increased risk of T2D and CVD. DATA SYNTHESIS: We searched PubMed, Embase, Web of Science, Cochrane CENTRAL, and Scopus up to October 11, 2024, for randomized controlled trials (RCTs) comparing MedD-based diets to control diets in adults. Studies reporting outcomes on glucose metabolism and GM composition were included. Random-effects meta-analyses were conducted on metabolic outcomes. GM findings were synthesized descriptively due to heterogeneity in sequencing methods and taxonomic reporting. Nine RCTs (n = 1337 participants) met the inclusion criteria. Compared with control diets, MedD interventions significantly reduced glycated hemoglobin (HbA1c) (mean difference -0.18, 95 % CI = -0.35, -0.01), LDL cholesterol (-0.10, 95 % CI = -0.19, -0.00), and triglycerides -0.20, 95 % CI = -0.28, -0.12). No significant effects were observed on fasting glucose, insulin, HOMA-IR, total cholesterol, or HDL cholesterol. A qualitative GM analysis showed increased α-diversity and enrichment of health-related taxa, including Akkermansia muciniphila and Roseburia spp. CONCLUSIONS: Our findings suggest that MedD interventions improve HbA1c, LDL cholesterol, and triglycerides, and promote beneficial GM changes. These may contribute to the metabolic benefits of the MedD. Future research should focus on individualized approaches, longer intervention periods, and mechanistic insights using multi-omics data to better understand the diet-microbiota-host interaction. PROTOCOL REGISTRATION: PROSPERO as CRD42023428016.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.